Seven deals raised a combined $1.2 billion this past week and first day returns averaged 16%. Performance was particularly strong for the healthcare space; Chinese cancer biotech Zai Lab led the pack, returning 55% on its first day,...read more
Celcuity, which is developing live cell diagnostic tests for cancer patients, raised $22.8 million by offering 2.4 million shares at $9.50, within the range of $8 to $10. It originally filed to offer 2.0 million shares. At $9.50, the pre-revenue company commands...read more
Seven deals are on the IPO calendar to raise a combined $1.6 billion in the week ahead. Chinese logistics provider Best leads the pack with an $869 million offering (the largest IPO of Q3), followed by leading Latin American...read more
Celcuity, which is developing live cell diagnostic tests for cancer patients, announced terms for its IPO on Thursday. The Minneapolis, MN-based company plans to raise $18 million by offering 2 million shares at a price range of $8 to $10. At the midpoint...read more
US IPO Weekly Recap: An active week as 7 IPOs average 16% pop
Seven deals raised a combined $1.2 billion this past week and first day returns averaged 16%. Performance was particularly strong for the healthcare space; Chinese cancer biotech Zai Lab led the pack, returning 55% on its first day,...read more
Tissue test: Celcuity prices upsized IPO above the midpoint at $9.50 to raise $23 million
Celcuity, which is developing live cell diagnostic tests for cancer patients, raised $22.8 million by offering 2.4 million shares at $9.50, within the range of $8 to $10. It originally filed to offer 2.0 million shares. At $9.50, the pre-revenue company commands...read more
US IPO Week Ahead: Most active week of the quarter with 7 IPOs, led by Alibaba-backed Best
Seven deals are on the IPO calendar to raise a combined $1.6 billion in the week ahead. Chinese logistics provider Best leads the pack with an $869 million offering (the largest IPO of Q3), followed by leading Latin American...read more
Pre-revenue diagnostics company Celcuity sets terms for $18 million IPO
Celcuity, which is developing live cell diagnostic tests for cancer patients, announced terms for its IPO on Thursday. The Minneapolis, MN-based company plans to raise $18 million by offering 2 million shares at a price range of $8 to $10. At the midpoint...read more